4- (3- amino- 4- (2,4,5- trifluorophenyl)butanoyl)- 3- (tert- butoxymethyl)piperazin- 2- one

10/01/2020 - "Therefore, evogliptin serves as a potential implication to protect lung fibrosis."
10/01/2020 - "Evogliptin exerts an anti-fibrosis effect on TGF-β induced lung fibroblast activation, which restrains ECM formation and decreases cell proliferation level in fibroblasts. "
01/01/2020 - "The present study demonstrates that evogliptin is protective against UUO-induced renal fibrosis, suggesting that its clinical applications could extend to the treatment of kidney disease of non-diabetic origin."
01/01/2020 - "Evogliptin attenuated UUO-induced renal atrophy and tubulointerstitial fibrosis. "
01/01/2020 - "Here, we report the beneficial effects of evogliptin on unilateral ureteral obstruction (UUO)-induced renal fibrosis in mice. "

01/01/2020 - "Efficacy and safety of evogliptin treatment in patients with type 2 diabetes: A multicentre, active-controlled, randomized, double-blind study with open-label extension (the EVERGREEN study)."
01/01/2019 - "Efficacy and safety of evogliptin in the treatment of type 2 diabetes mellitus in a Brazilian population: a randomized bridging study."
06/01/2022 - "Evogliptin for the treatment option for type 2 diabetes: an update of the literature."
01/01/2022 - "The efficacy and safety of evogliptin for type 2 diabetes mellitus: A systematic review and meta-analysis."
01/01/2021 - "Efficacy and Tolerability of Evogliptin in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis with Bayesian Inference Through a Quality-management System."

02/01/2017 - "In a prevention study, insulin sensitivity was preserved in evogliptin-treated mice after a 16-week treatment. "
02/01/2017 - "Conclusively, our findings suggest that evogliptin treatment ameliorates fatty liver by increasing insulin sensitivity and suppressing lipogenesis."
07/01/2021 - "Effects of the Combination of Evogliptin and Leucine on Insulin Resistance and Hepatic Steatosis in High-Fat Diet-Fed Mice."
02/01/2017 - "Moreover, reduction in plasma non-esterified fatty acids supported the improvement of insulin resistance by evogliptin treatment. "
02/01/2017 - "We previously reported that the novel DPP4 inhibitor evogliptin improves insulin resistance. "

09/14/2020 - "Protective Effects of Evogliptin on Steatohepatitis in High-Fat-Fed Mice."
02/01/2017 - "This study aimed to verify the therapeutic potential of evogliptin for fatty liver. "
09/14/2020 - "Evogliptin may alleviate steatohepatitis in HFD-fed mice by ameliorating steatosis and oxidative stress and by modulating mitophagy in the liver."
09/14/2020 - "We explored whether evogliptin (Evo), a dipeptidyl peptidase-4 inhibitor, protects against steatohepatitis in a high-fat diet (HFD)-fed mice and whether these effects involve modulation of mitophagy. "
02/01/2017 - "Conclusively, our findings suggest that evogliptin treatment ameliorates fatty liver by increasing insulin sensitivity and suppressing lipogenesis."

10/01/2019 - "This study demonstrates that the protective effect of evogliptin on atherosclerotic progression via inhibition of vascular inflammation. "
01/01/2021 - "Evogliptin Suppresses Calcific Aortic Valve Disease by Attenuating Inflammation, Fibrosis, and Calcification."
01/01/2016 - "Moreover, DA-1229 treatment significantly improved proteinuria, renal fibrosis and inflammation associated with decreased urinary nephrin loss, and kidney DPP4 activity. "
11/07/2023 - "Evogliptin tartrate effects on controlling inflammation and pain were evaluated by measuring rat plantar paw thickness, paw withdrawal threshold, dorsal root ganglion (DRG) resting membrane potential, DRG action potential firing, and cytokine (TNF-α and IL-1β) levels. "
11/07/2023 - "Methods: Forty male Sprague Dawley rats were divided into (N = 10 in each): (1) naïve, (2) complete Freund's adjuvant (CFA) inflammation + evogliptin tartrate (once for 10 mg/kg) (CFAE), (3) CFA + vehicle (same volume with normal saline with evogliptin tartrate/once) (CFAV), and (4) CFA + indomethacin (5 mg/mL/kg/1 time) (CFAI) groups. "